Clinical Trial

Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer

Enrolling by Invitation Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 17, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The standard treatment for locally advanced rectal cancer is neoadjuvant chemoradiotherapy followed by total mesorectal excision. While Immune checkpoint inhibitors are promising in the treatment of various cancers, the combination of radiotherapy and immunotherapy still lacks high-level evidence-based medicine, and the efficacy is still limited in rectal cancer. Thus, we designed a study on the efficacy and safety of intestinal microbiota transplantation combined with synchronous radiochemotherapy and immune checkpoint inhibitor xindilimab neoadjuvant therapy for locally advanced rectal cancer.
Trial Details
NCT Number NCT06931808
Lead Sponsor First Affiliated Hospital of Ningbo University
Conditions Localized Advanced Rectal Adenocarcinoma
Enrollment 20 participants
Start Date 2025-03-01
Primary Completion 2026-03-01 (estimated)
Study Completion 2028-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-17